|
1
|
Chen W, Zheng R, Baade PD, Zhang S, Zeng
H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China,
2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Li SD, Ma M, Li H, Waluszko A, Sidorenko
T, Schadt EE, Zhang DY, Chen R and Ye F: Cancer gene profiling in
non-small cell lung cancers reveals activating mutations in JAK2
and JAK3 with therapeutic implications. Genome Med. 9:892017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Díaz-Serrano A, Gella P, Jiménez E,
Zugazagoitia J and Paz-Ares Rodríguez L: Targeting egfr in lung
cancer: Current standards and developments. Drugs. 78:893–911.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ritter DI, Roychowdhury S, Roy A, Rao S,
Landrum MJ, Sonkin D, Shekar M, Davis CF, Hart RK, Micheel C, et
al: Somatic cancer variant curation and harmonization through
consensus minimum variant level data. Genome Med. 8:1172016.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Hensing T, Chawla A, Batra R and Salgia R:
A personalized treatment for lung cancer: Molecular pathways,
targeted therapies, and genomic characterization. Adv Exp Med Biol.
799:85–117. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Vendrell JA, Taviaux S, Béganton B,
Godreuil S, Audran P, Grand D, Clermont E, Serre I, Szablewski V,
Coopman P, et al: Detection of known and novel ALK fusion
transcripts in lung cancer patients using next-generation
sequencing approaches. Sci Rep. 7:125102017. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Saarenheimo J, Eigeliene N, Andersen H,
Tiirola M and Jekunen A: The value of liquid biopsies for guiding
therapy decisions in non-small cell lung cancer. Front Oncol.
9:1292019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng Y, Wang S, Han L, Liu P, Li H, Ren
X, Yu J and Hao X: Concurrent somatic mutations in driver genes
were significantly correlated with lymph node metastasis and
pathological types in solid tumors. Oncotarget. 8:68746–68757.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Ke EE and Wu YL: Afatinib in the
first-line treatment of epidermal-growth-factor-receptor
mutation-positive non-small cell lung cancer: A review of the
clinical evidence. Ther Adv Respir Dis. 10:256–264. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang S, Cang S and Liu D: Third-generation
inhibitors targeting EGFR T790M mutation in advanced non-small cell
lung cancer. J Hematol Oncol. 9:342016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang YC, Zhou Q and Wu YL: Efficacy of
crizotinib in first-line treatment of adults with ALK-positive
advanced NSCLC. Expert Opin Pharmacother. 17:1693–1701. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Gainor JF and Shaw AT: Novel targets in
non-small cell lung cancer: ROS1 and RET fusions. Oncologist.
18:865–875. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Illei PB, Belchis D, Tseng LH, Nguyen D,
De Marchi F, Haley L, Riel S, Beierl K, Zheng G, Brahmer JR, et al:
Clinical mutational profiling of 1006 lung cancers by next
generation sequencing. Oncotarget. 8:96684–96696. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Allegretti M, Fabi A, Buglioni S, Martayan
A, Conti L, Pescarmona E, Ciliberto G and Giacomini P: Tearing down
the walls: FDA approves next generation sequencing (NGS) assays for
actionable cancer genomic aberrations. J Exp Clin Cancer Res.
37:472018. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang YC, Zhou Q and Wu YL: The emerging
roles of NGS-based liquid biopsy in non-small cell lung cancer. J
Hematol Oncol. 10:1672017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Miranda E, Destro A, Malesci A, Balladore
E, Bianchi P, Baryshnikova E, Franchi G, Morenghi E, Laghi L,
Gennari L and Roncalli M: Genetic and epigenetic changes in primary
metastatic and nonmetastatic colorectal cancer. Br J Cancer.
95:1101–1107. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Malapelle U, Mayo de-Las-Casas C, Rocco D,
Garzon M, Pisapia P, Jordana-Ariza N, Russo M, Sgariglia R, De Luca
C, Pepe F, et al: Development of a gene panel for next-generation
sequencing of clinically relevant mutations in cell-free DNA from
cancer patients. Br J Cancer. 116:802–810. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li H and Durbin R: Fast and accurate short
read alignment with Burrows-Wheeler transform. Bioinformatics.
25:1754–1760. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
McKenna A, Hanna M, Banks E, Sivachenko A,
Cibulskis K, Kernytsky A, Garimella K, Altshuler D, Gabriel S, Daly
M and DePristo MA: The genome analysis toolkit: A MapReduce
framework for analyzing next-generation DNA sequencing data. Genome
Res. 20:1297–1303. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cibulskis K, Lawrence MS, Carter SL,
Sivachenko A, Jaffe D, Sougnez C, Gabriel S, Meyerson M, Lander ES
and Getz G: Sensitive detection of somatic point mutations in
impure and heterogeneous cancer samples. Nat Biotechnol.
31:213–219. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Sherry ST, Ward MH, Kholodov M, Baker J,
Phan L, Smigielski EM and Sirotkin K: dbSNP: The NCBI database of
genetic variation. Nucleic Acids Res. 29:308–311. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Tassios PT and Moran-Gilad J: Bacterial
next generation sequencing (NGS) made easy. Clin Microbiol Infect.
24:332–334. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cabanillas R, Diñeiro M, Castillo D,
Pruneda PC, Penas C, Cifuentes GA, de Vicente Á, Durán NS, Álvarez
R, Ordóñez GR and Cadiñanos J: A novel molecular diagnostics
platform for somatic and germline precision oncology. Mol Genet
Genomic Med. 5:336–359. 2017. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Forde PM and Ettinger DS: Managing
acquired resistance in EGFR-mutated non-small cell lung cancer.
Clin Adv Hematol Oncol. 13:528–532. 2015.PubMed/NCBI
|
|
25
|
Zhao D, Chen X, Qin N, Su D, Zhou L, Zhang
Q, Li X, Zhang X, Jin M and Wang J: The prognostic role of
EGFR-TKIs for patients with advanced non-small cell lung cancer.
Sci Rep. 7:403742017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kucharczuk CR, Ganetsky A and Vozniak JM:
Drug-drug interactions, safety, and pharmacokinetics of EGFR
tyrosine kinase inhibitors for the treatment of non-small cell lung
cancer. J Adv Pract Oncol. 9:189–200. 2018.PubMed/NCBI
|
|
27
|
Ramalingam SS, Yang JC, Lee CK, Kurata T,
Kim DW, John T, Nogami N, Ohe Y, Mann H, Rukazenkov Y, et al:
Osimertinib as first-line treatment of EGFR mutation-positive
advanced non-small-cell lung cancer. J Clin Oncol. 36:841–849.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sequist LV, Waltman BA, Dias-Santagata D,
Digumarthy S, Turke AB, Fidias P, Bergethon K, Shaw AT, Gettinger
S, Cosper AK, et al: Genotypic and histological evolution of lung
cancers acquiring resistance to EGFR inhibitors. Sci Transl Med.
3:75ra262011. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ludovini V, Bianconi F, Pistola L, Chiari
R, Minotti V, Colella R, Giuffrida D, Tofanetti FR, Siggillino A,
Flacco A, et al: Phosphoinositide-3-kinase catalytic alpha and KRAS
mutations are important predictors of resistance to therapy with
epidermal growth factor receptor tyrosine kinase inhibitors in
patients with advanced non-small cell lung cancer. J Thorac Oncol.
6:707–715. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li S, Li L, Zhu Y, Huang C, Qin Y, Liu H,
Ren-Heidenreich L, Shi B, Ren H, Chu X, et al: Coexistence of EGFR
with KRAS, or BRAF, or PIK3CA somatic mutations in lung cancer: a
comprehensive mutation profiling from 5125 Chinese cohorts. Br J
Cancer. 110:2812–2820. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Brose MS, Volpe P, Feldman M, Kumar M,
Rishi I, Gerrero R, Einhorn E, Herlyn M, Minna J, Nicholson A, et
al: BRAF and RAS mutations in human lung cancer and melanoma.
Cancer Res. 62:6997–7000. 2002.PubMed/NCBI
|
|
32
|
Cheng DT, Prasad M, Chekaluk Y, Benayed R,
Sadowska J, Zehir A, Syed A, Wang YE, Somar J, Li Y, et al:
Comprehensive detection of germline variants by MSK-IMPACT, a
clinical diagnostic platform for solid tumor molecular oncology and
concurrent cancer predisposition testing. BMC Med Genomics.
10:332017. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Wheler JJ, Moulder SL, Naing A, Janku F,
Piha-Paul SA, Falchook GS, Zinner R, Tsimberidou AM, Fu S, Hong DS,
et al: Anastrozole and everolimus in advanced gynecologic and
breast malignancies: Activity and molecular alterations in the
PI3K/AKT/mTOR pathway. Oncotarget. 5:3029–3038. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Moroney J, Fu S, Moulder S, Falchook G,
Helgason T, Levenback C, Hong D, Naing A, Wheler J and Kurzrock R:
Phase I study of the antiangiogenic antibody bevacizumab and the
mTOR/hypoxia-inducible factor inhibitor temsirolimus combined with
liposomal doxorubicin: Tolerance and biological activity. Clin
Cancer Res. 18:5796–5805. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mackay HJ, Eisenhauer EA, Kamel-Reid S,
Tsao M, Clarke B, Karakasis K, Werner HM, Trovik J, Akslen LA,
Salvesen HB, et al: Molecular determinants of outcome with
mammalian target of rapamycin inhibition in endometrial cancer.
Cancer. 120:603–610. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Lovly C, Horn L and Pao W: PIK3CA
c.1633G>A (E545K) mutation in non-small cell lung cancer. my
cancer genome. https://www.mycancergenome.org/content/disease/lung-cancer/pik3ca/8/(Updated
January 13). 2017
|
|
37
|
Fiala O, Pesek M, Finek J, Benesova L,
Belsanova B and Minarik M: The dominant role of G12C over other
KRAS mutation types in the negative prediction of efficacy of
epidermal growth factor receptor tyrosine kinase inhibitors in
non-small cell lung cancer. Cancer Genet. 206:26–31. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Riely GJ and Ladanyi M: KRAS mutations: An
old oncogene becomes a new predictive biomarker. J Mol Diagn.
10:493–495. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Riely GJ, Marks J and Pao W: KRAS
mutations in non-small cell lung cancer. Proc Am Thorac Soc.
6:201–205. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Bhattacharya S, Socinski MA and Burns TF:
KRAS mutant lung cancer: Progress thus far on an elusive
therapeutic target. Clin Transl Med. 4:352015. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jänne PA, Shaw AT, Pereira JR, Jeannin G,
Vansteenkiste J, Barrios C, Franke FA, Grinsted L, Zazulina V,
Smith P, et al: Selumetinib plus docetaxel for KRAS-mutant advanced
non-small-cell lung cancer: A randomised, multicentre,
placebo-controlled, phase 2 study. Lancet Oncol. 14:38–47. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Carretero J, Shimamura T, Rikova K,
Jackson AL, Wilkerson MD, Borgman CL, Buttarazzi MS, Sanofsky BA,
McNamara KL, Brandstetter KA, et al: Integrative genomic and
proteomic analyses identify targets for Lkb1-deficient metastatic
lung tumors. Cancer Cell. 17:547–559. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Chen Z, Cheng K, Walton Z, Wang Y, Ebi H,
Shimamura T, Liu Y, Tupper T, Ouyang J, Li J, et al: A murine lung
cancer co-clinical trial identifies genetic modifiers of
therapeutic response. Nature. 483:613–617. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Infante JR, Fecher LA, Falchook GS,
Nallapareddy S, Gordon MS, Becerra C, DeMarini DJ, Cox DS, Xu Y,
Morris SR, et al: Safety, pharmacokinetic, pharmacodynamic, and
efficacy data for the oral MEK inhibitor trametinib: a phase 1
dose-escalation trial. Lancet Oncol. 13:773–781. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Xing X, Cai W, Shi H, Wang Y, Li M, Jiao J
and Chen M: The prognostic value of CDKN2A hypermethylation in
colorectal cancer: A meta-analysis. Br J Cancer. 108:2542–2548.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Padhi SS, Roy S, Kar M, Saha A, Roy S,
Adhya A, Baisakh M and Banerjee B: Role of CDKN2A/p16 expression in
the prognostication of oral squamous cell carcinoma. Oral Oncol.
73:27–35. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Kim N, Song M, Kim S, Seo Y, Kim Y and
Yoon S: Differential regulation and synthetic lethality of
exclusive RB1 and CDKN2A mutations in lung cancer. Int J Oncol.
48:367–375. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Gopalan PK, Pinder MC, Chiappori A, Ivey
AM, Villegas AG and Kaye FJ: A phase II clinical trial of the
CDK4/6 inhibitor palbociclib (PD0332991) in previously treated,
advanced non-small cell lung cancer (NSCLC) patients with
inactivated CDKN2A. J Clin Oncol. 32:80772014. View Article : Google Scholar
|
|
49
|
Logan JE, Mostofizadeh N, Desai AJ, VON
Euw E, Conklin D, Konkankit V, Hamidi H, Eckardt M, Anderson L,
Chen HW, et al: PD-0332991, a potent and selective inhibitor of
cyclin-dependent kinase 4/6, demonstrates inhibition of
proliferation in renal cell carcinoma at nanomolar concentrations
and molecular markers predict for sensitivity. Anticancer Res.
33:2997–3004. 2013.PubMed/NCBI
|
|
50
|
Young RJ, Waldeck K, Martin C, Foo JH,
Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, et al:
Loss of CDKN2A expression is a frequent event in primary invasive
melanoma and correlates with sensitivity to the CDK4/6 inhibitor
PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res.
27:590–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Konecny GE, Winterhoff B, Kolarova T, Qi
J, Manivong K, Dering J, Yang G, Chalukya M, Wang HJ, Anderson L,
et al: Expression of p16 and retinoblastoma determines response to
CDK4/6 inhibition in ovarian cancer. Clin Cancer Res. 17:1591–1602.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Finn RS, Dering J, Conklin D, Kalous O,
Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Kanwal M, Ding XJ and Cao Y: Familial risk
for lung cancer. Oncol Lett. 13:535–542. 2017. View Article : Google Scholar : PubMed/NCBI
|
